Login to Your Account



Marinus 'Sage' approach flexible with ganaxolone

By Randy Osborne
Staff Writer

Monday, January 23, 2017

Jaakko Lappalainen, vice president of clinical development for Marinus Pharmaceuticals Inc., told BioWorld Today that early phase II success with ganaxolone against CDKL5 seizure disorder should not necessarily have taken anyone by surprise.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription